What is Hepatitis?

Get an overview of Hepatitis.

Message Board

Share your experience with others.

Donations

Help enhance our programs.

Home | Hepatitis C News

HEPATITIS C NEWS


    • CDC Analysis Recommends Enhanced Acute Hepatitis C Surveillance
      READ NEWS
    • Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE
      READ NEWS
    • Non response to peginterferon alfa and ribavirin in IL28B CC & CT patients can be overcome by high dose continuous interferon alfa-2b administration in combination with ribavirin for chronic hepatitis C
      READ NEWS
    • GI-5005 Therapeutic Vaccine Plus Peg-IFN/Ribavirin Improves Sustained Virologic Response Versus Peg-IFN/Ribavirin In Prior Non-Responders With Genotype 1 Chronic HCV Infection
      READ NEWS
    • Telaprevir in Combination with Peginterferon Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naïve Genotype 1 HCV Patients who Achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study
      READ NEWS
    • Response-Guided Therapy (RGT) with Boceprevir (BOC) + Peginterferon alfa-2b/Ribavirin (P/R) for Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype (G) 1 Was Similar to a 48-Wk Fixed-Duration Regimen with BOC + P/R in SPRINT-2
      READ NEWS
    • Completely individualized treatment durations with peginterferon-alfa-2b and ribavirin in HCV genotype 1-infected patients and importance of IL28B genotype (INDIV-2 study)
      READ NEWS
    • Long-term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis of the EXTEND Study
      READ NEWS
    • Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients with advanced chronic hepatitis C: extended follow - up results from the HALT - C Trial
      READ NEWS
    • FDA Issues Guidance for Development of Directing-acting Antiviral Drugs for Hepatitis C
      READ NEWS
    • Highest Rates of Hepatitis C Virus Transmission Found in Egypt
      READ NEWS
    • Vertex hep C drug works on many in 24 weeks: Study
      READ NEWS
    • KERRY & HONDA: Disrupting a deadly disease
      READ NEWS
    • Hispanics And Asians Less Likely To Receive Liver Transplants
      READ NEWS
    • FDA Approves Rapid Test for Antibodies to Hepatitis C Virus
      READ NEWS
    • Vitamin A and Treatment
      READ NEWS
    • Efforts to Up Minority Organ Donations Show Success
      READ NEWS
    • Study Finds Beta Blockers Alone More Effective for First Variceal Bleeding
      READ NEWS
    • Antiviral Therapy during Compensated Cirrhosis Most Cost-Effective Approach Treatment
      READ NEWS
    • Study Finds Poor Compliance with Cirrhosis Surveillance Recommendations Less than 20% of Qualified Patients Are Regularly Monitored
      READ NEWS
    • Peginterferon alfa-2B and Ribavirin for Liver Transplant Patients Yields 30% HCV SVR
      READ NEWS
    • Modest" Results With Nitazoxanide for HCV Genotype 1 Nonresponders
      READ NEWS
    • Study Links Liver Transplantation to Accelerated Cellular Aging
      READ NEWS
    • FDA Considers Expanded Use of HCV Drugs
      READ NEWS
    • Liver Donations from Living Donors Increase 42% after Educational Intervention
      READ NEWS
    • Infectious Disease Screening
      READ NEWS
    • Telaprevir Raises Response Rates in Hepatitis C
      READ NEWS
    • HCV Polymerase Inhibitor VX-222 Demonstrates Good Safety and Antiviral Activity in Treatment-naive Genotype 1 Hepatitis C Patients
      READ NEWS
    • HCV Protease Inhibitor Danoprevir (RG7227/ITMN-191) Shows Antiviral Activity at Lower Doses When Boosted with Ritonavir
      READ NEWS
    • HCV Protease Inhibitor Boceprevir Demonstrates Durable Sustained Response with No Late Relapse
      READ NEWS
    • Vertex Will Study All-Oral Regimen of HCV Protease Inhibitor Telaprevir plus Polymerase Inhibitor VX-222
      READ NEWS
    • U.S. Doctors Sanction Transplant Criteria for Liver Cancer Patients
      READ NEWS
    • Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies
      READ NEWS
    • Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
      READ NEWS
    • Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
      READ NEWS
    • Liver Donations from Living Donors Increase 42% after Educational Intervention
      READ NEWS
    • Vaccines May Lower Viral Load Improve Treatment Response
      READ NEWS
    • African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C
      READ NEWS
    • Metabolic Factors That Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV Patients
      READ NEWS
    • Weight Loss: A Modifiable Lifestyle Parameter That Can Alter HCV Liver Disease Progression
      READ NEWS
    • Silent Epidemic of Viral Hepatitis May Lead to Boom in Serious Liver Disease
      READ NEWS
    • Direct Antivirals Can Beat HCV Without Interferon
      READ NEWS
    • HCV Response Linked Strongly to Gene Variant
      READ NEWS
    • Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), An Investigational, Once-Daily Protease Inhibitor For Hepatitis C
      READ NEWS
    • More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen
      READ NEWS
    • Sprint 1 Study, Phase 2, Boceprevir
      READ NEWS
    • Pegylated Interferon Lambda Demonstrates Good Antiviral Activity, May Cause Fewer Side Effects than Interferon Alfa
      READ NEWS
    • Coffee Could Stall Liver Disease Progression
      READ NEWS
    • Hepatitis C Drug Development at a Crossroads - Comments from the Editors
      READ NEWS
    • Hypertension and Diabetes Are Concern in Long-Term Care of Liver Transplant Patients
      READ NEWS
    • The FDA has just issued new warnings in the package inserts for alpha interferons
      READ NEWS
    • Women, Blacks, Medicare Recipients Less Likely To Be Evaluated For Liver Transplantation
      READ NEWS
    • New Biomarker Predicts Response to Hepatitis C Treatment
      READ NEWS
    • Protein & Cholesterol May Increase Risk Of Cirrhosis & Hepatocellular Carcinoima
      READ NEWS
    • Weight-Related Factors Tied to Outcomes of Chronic Hepatitis C
      READ NEWS
    • Head-to-Head Trial Finds HCV Regimens Equal
      READ NEWS
    • Interferon and Ribavirin Second-Line Option for Hepatitis C
      READ NEWS
    • DDW: Interferon Has Long-Term Histo Benefits in HCV
      READ NEWS
    • FDA May Restrict Acetaminophen
      READ NEWS
    • Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1
      READ NEWS
    • DDW: Telaprevir Improves HCV Clearance in Resistant Patients
      READ NEWS
    • Hypothyroidism In Women Associated With Liver Cancer
      READ NEWS
    • Sustained Response Seen with New Hepatitis C Drug
      READ NEWS
    • Re-treatment of Chronic Hepatitis C Patients Who Do Not Respond to Pegylated Interferon Alfa-2b (PegIntron)
      READ NEWS
    • Promising Promising Early Results from the First Clinical Trial of a Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C
      READ NEWS
    • Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C
      READ NEWS
    • HCV Vaccine Development
      READ NEWS
    • Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
      READ NEWS
    • Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
      READ NEWS
    • Response To Therapy In Chronic Hepatitis C Predicted By 2-Day Results
      READ NEWS
    • Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors
      READ NEWS
    • Hepatitis C Linked to Increased Risk of Intrahepatic Cholangiocarcinoma
      READ NEWS
    • Liver Biopsies Indicate Persistent Inflammation and Fibrosis in HCV Antibody Positive People with Undetectable HCV RNA
      READ NEWS
    • Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study with R7128 in Treatment Naive HCV Patients
      READ NEWS
    • Human Genome Sciences Announces Initiation of Phase 2b Trial 0f Albuferon Dosed Monthly in Chronic Hepatitis C
      READ NEWS
    • Although Hepatitis C Treatment Reduces The Virus, Liver Damage Continues
      READ NEWS
    • Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint In Phase 3 Trial In Chronic Hepatitis C
      READ NEWS
    • Pegylated interferon alpha2a is more effective in some hepatitis C patients with specific genotypes than the alpha2b form of the drug, an Italian researcher said
      READ NEWS
    • HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
      READ NEWS
    • Hepatitis C patients may have abnormal blood sugar
      READ NEWS
    • FDA Approves Nexavar for Patients with Inoperable Liver Cancer
      READ NEWS
    • Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years
      READ NEWS
    • Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
      READ NEWS
    • Safety and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients
      READ NEWS
    • Insulin Resistance Independently Associated With Chronic Hepatitis C
      READ NEWS
    • Pathology of Chronic Hepatitis C in Children: Peds-C Trial
      READ NEWS
    • Silymarin (Milk Thistle) Does Not Affect Hepatitis C Virus Activity or ALT Levels in HCV Patients, but Users Report Fewer Symptoms and Better Quality of Life than Non Users
      READ NEWS
    • Acute Hepatitis C Infection and Spontaneous Viral Clearance in Adults and Children
      READ NEWS
    • How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50?
      READ NEWS
    • Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians
      READ NEWS
    • HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C
      READ NEWS
    • Use of Epoetin (EPO) to Manage Anemia in Chronic Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
      READ NEWS
    • Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis
      READ NEWS
    • HCV Care by Liver Specialists or Community-Based Practices: Pro & Con
      READ NEWS
    • Decreased HCV-specific Immunity in African-Americans May Help Explain Poorer Response to Antiviral Therapy
      READ NEWS
    • 400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV
      READ NEWS
    • Liver Stiffness Predicts Portal Hypertension in HCV Cirrhosis
      READ NEWS
    • EASL: Sustained Virologic Response Equals Cure for HCV Infection
      READ NEWS
    • Racial Differences Seen In Steatosis In Patients With Hepatitis C
      READ NEWS
    • New Vaccine Schedule Offers Protection Against Hepatitis A And Hepatitis B
      READ NEWS
    • Interferon Gamma Does Not Reverse Fibrosis in Hepatitis C Patients with Advanced Liver Disease
      READ NEWS
    • Hepatitis C in African Americans
      READ NEWS
    • Three Studies Examine Syringe Exchange Policies in the U.S.
      READ NEWS
    • Short-course Pegylated Interferon for Acute Hepatitis C
      READ NEWS
    • Heavy-Drinking Women with HCV Infection Cut Decade Off Life
      READ NEWS
    • Treatment Response in Cirrhotic Hepatitis C Patients with Portal Hypertension
      READ NEWS
    • Integrating Medical and Mental Health Care Improves Likelihood of Initiation and Adherence to Hepatitis C Treatment
      READ NEWS
    • Rapid Decline of HCV RNA in Patients Treated with VX-950
      READ NEWS
    • Predicting Survival After Liver Transplant
      READ NEWS
    • Patients Who Recover from Hepatitis C Have Lower Risk of Reinfection
      READ NEWS
    • New Therapy Significantly Increases Platelet Count
      READ NEWS
    • Is Hepatitis A and B Screening and Vaccination in Chronic Hepatitis C Patients Effective?
      READ NEWS
    • Sustained Virological Response to PegIntron Plus Ribavirin in Asian and Hispanic Patients
      READ NEWS

Patient Assistance and GoodSearch Patient Assistance NOW and GoodSearch Patient Assistance NOW and GoodSearch

Home | What is hepatitis? | About Us | Who's Involved | Hepatitis C News | Upcoming Events | Brochures | Gift Cards | Related Links

Noteworthy Bulletins | Message Board | All the Joy | Privacy Statement | Contact Information

© 2009 Hepatitis C Association Inc, All rights reserved.